PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization
by Rana MN, Lu J, Xue E, Ruan J, Liu Y, Zhang L, Dhar R, Li Y, Hu Z, Zhou J, Ma W and Tang H (2021). Front. Pharmacol. 12:643215. doi: 10.3389/fphar.2021.643215
Due to a production error, a footnote (†) to the author list was incomplete and was also incorrectly not applied to the author Mohammad Nasiruddin Rana. The correct author list and footnote are as follows:
Mohammad Nasiruddin Rana1†, Jie Lu2†, Enfu Xue1†, Jingjing Ruan1†, Yuting Liu1†, Lejun Zhang1, Rana Dhar1, Yajun Li1, Zhengqiang Hu1, Jie Zhou3, Wangqian Ma4* and Huifang Tang1*
† These authors have contributed equally to this work and share first authorship
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: ulcerative colitis, PF-04447943, inflammasome, Treg/Th17 cell balance, PDE9A, oxidative stress
Citation: Frontiers Production Office (2024) Erratum: PDE9 inhibitor PF-04447943 attenuates DSS-induced colitis by suppressing oxidative stress, inflammation, and regulating T-cell polarization. Front. Pharmacol. 15:1393029. doi: 10.3389/fphar.2024.1393029
Received: 28 February 2024; Accepted: 28 February 2024;
Published: 11 March 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org